Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company [Yahoo! Finance]
Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]
Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]
Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.
Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]